Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Human T-cell lymphotropic virus type-1 infection and risk of cancer: 15.4 year longitudinal study among atomic bomb survivors in Nagasaki, Japan.

Arisawa K, Soda M, Akahoshi M, Fujiwara S, Uemura H, Hiyoshi M, Takeda H, Kashino W, Suyama A.

Cancer Sci. 2006 Jun;97(6):535-9.

2.

Human T-lymphotropic virus type-I infection, antibody titers and cause-specific mortality among atomic-bomb survivors.

Arisawa K, Soda M, Akahoshi M, Matsuo T, Nakashima E, Tomonaga M, Saito H.

Jpn J Cancer Res. 1998 Aug;89(8):797-805.

PMID:
9765614
3.

Risk factors for primary breast cancer in Japan: 8-year follow-up of atomic bomb survivors.

Goodman MT, Cologne JB, Moriwaki H, Vaeth M, Mabuchi K.

Prev Med. 1997 Jan-Feb;26(1):144-53.

PMID:
9010910
4.

A nested case-control study of risk factors for adult T-cell leukemia/lymphoma among human T-cell lymphotropic virus type-I carriers in Japan.

Arisaw K, Katamine S, Kamihira S, Kurokawa K, Sawada T, Soda M, Doi H, Saito H, Shirahama S.

Cancer Causes Control. 2002 Sep;13(7):657-63.

PMID:
12296513
5.

Geographic distribution of the incidence of adult T-cell leukemia/lymphoma and other malignancies in nagasaki prefecture, Japan.

Arisawa K, Soda M, Shirahama S, Saito H, Takamura N, Yamaguchi M, Odagiri K, Nakagoe T, Suyama A, Doi H.

Jpn J Clin Oncol. 2002 Aug;32(8):301-6.

PMID:
12411568
6.

Mortality among inhabitants of an HTLV-I endemic area in Japan.

Iwata K, Ito S, Saito H, Ito M, Nagatomo M, Yamasaki T, Yoshida S, Suto H, Tajima K.

Jpn J Cancer Res. 1994 Mar;85(3):231-7.

PMID:
8188520
7.

Human T lymphotropic virus type 1 infection and gastric cancer development in Japan.

Matsumoto S, Yamasaki K, Tsuji K, Shirahama S.

J Infect Dis. 2008 Jul 1;198(1):10-5. doi: 10.1086/588733.

PMID:
18544011
8.

Low prevalence of human T cell lymphotropic virus type 1 infection in patients with gastric cancer.

Hirata T, Nakamoto M, Nakamura M, Kinjo N, Hokama A, Kinjo F, Fujita J.

J Gastroenterol Hepatol. 2007 Dec;22(12):2238-41.

PMID:
18031387
9.

Profiles of non-cancer diseases in atomic bomb survivors.

Kodama K, Fujiwara S, Yamada M, Kasagi F, Shimizu Y, Shigematsu I.

World Health Stat Q. 1996;49(1):7-16. Review.

PMID:
8896251
10.

A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan.

Boschi-Pinto C, Stuver S, Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, Mueller N.

J Infect Dis. 2000 Jan;181(1):35-41.

PMID:
10608748
11.

Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study.

Murphy EL, Glynn SA, Fridey J, Smith JW, Sacher RA, Nass CC, Ownby HE, Wright DJ, Nemo GJ.

Arch Intern Med. 1999 Jul 12;159(13):1485-91.

PMID:
10399901
12.

Anti-Human T-lymphotropic virus type-I antibodies in atomic-bomb survivors.

Matsuo T, Nakashima E, Carter RL, Neriishi K, Mabuchi K, Akiyama M, Shimaoka K, Kinoshita K, Tomonaga M, Ichimaru M.

J Radiat Res. 1995 Mar;36(1):8-16.

13.

Incidence of multiple primary cancers in Nagasaki atomic bomb survivors: association with radiation exposure.

Nakashima M, Kondo H, Miura S, Soda M, Hayashi T, Matsuo T, Yamashita S, Sekine I.

Cancer Sci. 2008 Jan;99(1):87-92. Epub 2007 Nov 2.

14.

Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan.

Koga Y, Iwanaga M, Soda M, Inokuchi N, Sasaki D, Hasegawa H, Yanagihara K, Yamaguchi K, Kamihira S, Yamada Y.

J Med Virol. 2010 Apr;82(4):668-74. doi: 10.1002/jmv.21738.

PMID:
20166187
15.

Decreased survival of HTLV-I carriers in leprosy patients from the Democratic Republic of the Congo: a historical prospective study.

Lechat MF, Shrager DI, Declercq E, Bertrand F, Blattner WA, Blumberg BS.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 15;15(5):387-90.

PMID:
9342260
16.

Are cancer risks associated with exposures to ionising radiation from internal emitters greater than those in the Japanese A-bomb survivors?

Little MP, Hall P, Charles MW.

Radiat Environ Biophys. 2007 Nov;46(4):299-310. Epub 2007 Jul 17.

PMID:
17639450
17.

Human T-lymphotropic virus type-I infection, survival and cancer risk in southwestern Japan: a prospective cohort study.

Arisawa K, Sobue T, Yoshimi I, Soda M, Shirahama S, Doi H, Katamine S, Saito H, Urata M.

Cancer Causes Control. 2003 Nov;14(9):889-96.

PMID:
14682446
18.

Cancer and non-cancer effects in Japanese atomic bomb survivors.

Little MP.

J Radiol Prot. 2009 Jun;29(2A):A43-59. doi: 10.1088/0952-4746/29/2A/S04. Epub 2009 May 19. Review.

PMID:
19454804
19.

A case-control study of risk factors for seropositivity to human T-lymphotropic virus type I (HTLV-I) in Jamaica.

Murphy EL, Wilks R, Hanchard B, Cranston B, Figueroa JP, Gibbs WN, Murphy J, Blattner WA.

Int J Epidemiol. 1996 Oct;25(5):1083-9.

PMID:
8921498
20.

Prevalence of anti-hepatitis C virus antibody and chronic liver disease among atomic bomb survivors.

Fujiwara S, Kusumi S, Cologne J, Akahoshi M, Kodama K, Yoshizawa H.

Radiat Res. 2000 Jul;154(1):12-9.

PMID:
10856960

Supplemental Content

Support Center